Who We Are

At innoVitro, our team of scientists and engineers leads the industry as a Contract Research Organization (CRO) specializing in human-based cell analytics.

We excel in assessing functional and structural cellular readouts – including cell contractility, viability, connectivity and electrophysiology – with unmatched precision and throughput. Our cutting-edge technologies focus on speedlabel-free operationsreal-time analysis.

Our services are tailored to the needs of drug discovery, encompassing comprehensive preclinical safety assessments, toxicity evaluations, and efficacy studies of pharmaceutical and nutritional industries.

Reach out to test the effects of small moleculesbiopharmaceuticalsvector-based therapeuticsimmune therapeuticssiRNAs/miRNAsantibodies!

Get in touch

FLEXcyte Plate with flexible cell culture substrate

Cell-Based Assay Services

Explore our cell-based assay services, designed to monitor dynamic functional and cellular changes over time to gain valuable insights into contractile, morphological or general cellular responses.

Technologies

Discover our state-of-the-art cell-based assay technologies, the cornerstone of our services designed to elevate your cellular research fast and effectively!

FLEXcyte 96

CardioExcyte 96

AtlaZ

Latest News

Ensuring Safety and Quality of Botanical Extracts in Food and Dietary Supplements

Meet us at the 4th Next-Gen Organ-On-Chip & Organoids Workshop taking place in Basel, Switzerland, 13th - 14th of February 2025.

We will be attending the Society of Toxicology (SOT) conference and ToxExpo in Orlando, March 16 -20.

Our Trusted Partners & Clients

innoVitro exemplifies outstanding customer service with a readily available and fantastic team. As members of the HESI Cardiac Safety Technical Committee, they are dedicated to improving public health by reducing unexpected cardiovascular side effects. Their up-to-date insights and expertise in diverse assays make them an exceptional collaborative partner.

Sonja Stölzle-Feix

Director Scientific Affairs

Nanion Technologies

We were very pleased with our choice to engage innoVitro’s contractility service. The studies using human iPSC-derived cardiomyocytes were tailored to our needs to provide results comparable to already existing (in house) data and the fast execution followed by a comprehensive study report completed the service perfectly.

Nina Glaser

Head of Early Safety Electrophysiology

Merck Healthcare KGaA

The FLEXcyte brings another dimension to iPS-derived cardiomyocyte based assays. Measuring contractility in such a direct and easy way allows us to understand the cell functionality better and will help us in both our product development and safety pharmacology research.

Choong-Seong (Henry) Han DDS PhD

CEO, Founder

NEXEL Co., Ltd.

Outstanding electrophysiology service on all levels. Working with innoVitro was such a streamlined experience. The dedicated team offers a friendly service with professional advice during every stage of the project. Very responsive and delivered as promised.

Prof. Dr. med. Jin Li

Head of Autoimmune Channelopathies

University of Zurich

I wholeheartedly recommend the CardioExcyte 96 and FLEXcyte 96 to any scientist seeking to explore cardiac contractility with precision and efficiency. These systems have undoubtedly enhanced the depth and accuracy of our research, contributing significantly to answering our scientific questions.

Dr. Yuanzhao (Nick) Cao

Institute for Molecular Bioscience

The University of Queensland

O
O
O
O
O

Human Cell-Based Assays

Fast.

Predictive.

Competitive.